Aspartame as a Possible Carcinogen

Record	OBS-0311
Category	Health/Vaccines
Status	PARTIALLY SUBSTANTIATED
Summary	In July 2023, the WHO's International Agency for Research on Cancer (IARC) classified aspartame as 'possibly carcinogenic to humans' (Group 2B) based on limited evidence for liver cancer. The FDA and other regulators disagree, maintaining that aspartame is safe at current permitted levels. This has sparked public concern and potential litigation.
Origin	The classification was announced on July 14, 2023, by IARC and JECFA, following a review of existing scientific literature. The controversy stems from differing interpretations of the same evidence by different regulatory bodies.
Claimed	Aspartame is possibly carcinogenic to humans, specifically linked to hepatocellular carcinoma (a type of liver cancer). The evidence for carcinogenicity is limited but warrants further investigation. Consuming aspartame within the acceptable daily intake (40 mg/kg body weight) is safe, but exceeding it may pose risks.
Evidence / consensus	IARC classified aspartame as Group 2B (possibly carcinogenic) based on limited evidence. However, JECFA, FDA, and other regulatory bodies conclude that aspartame is safe at current permitted levels, citing significant shortcomings in the studies IARC relied on. The evidence is not convincing for a causal link to cancer in humans.

> OBSERVER NOTE:
A classic case of hazard vs. risk. IARC flags a potential hazard; regulators say the risk at real-world exposure is negligible. The public hears 'possibly carcinogenic' and the lawsuits begin.

Sources

Sources are external and provided for verification. Listing does not imply the Observer endorses their claims.